Dr. Maloney on CAR T-Cell Product in B-Cell Lymphoma

David Maloney, MD, PhD
Published: Tuesday, Dec 19, 2017



David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the preliminary safety data of the chimeric antigen receptor (CAR) T-cell product, JCAR017, in relapsed/refractory aggressive B-cell lymphoma.

JCAR017 is directed against CD19 and is in multicenter clinical trials for patients with aggressive large B-cell lymphoma. The product is different from other CAR T cells since it targets a selected population, explains Maloney.

According to Maloney, being able to give the T cells in a defined mixture of CD4 and CD8 cells creates a better relationship between the dose response and the dose toxicity.
 


David Maloney, MD, PhD, professor of medicine, Division of Oncology, University of Washington, Clinical Research Division, Fred Hutchinson Cancer Research Center, discusses the preliminary safety data of the chimeric antigen receptor (CAR) T-cell product, JCAR017, in relapsed/refractory aggressive B-cell lymphoma.

JCAR017 is directed against CD19 and is in multicenter clinical trials for patients with aggressive large B-cell lymphoma. The product is different from other CAR T cells since it targets a selected population, explains Maloney.

According to Maloney, being able to give the T cells in a defined mixture of CD4 and CD8 cells creates a better relationship between the dose response and the dose toxicity.
 

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x